Daiichi Sankyo’s ADC U3-1402 Shows Tumor Reduction in NSCLC Patients: Preliminary PI Data

Daiichi Sankyo has presented preliminary data from a PI study of its HER3 targeting antibody drug conjugate (ADC) U3-1402 in non-small cell lung cancer (NSCLC) patients, showing a reduction in tumor size in all evaluable patients. The study enrolled 23...read more